Ask me later
Ask me later
How likely are you to recommend Redeye to a friend or colleague?
1
2
3
4
5
6
7
8
9
10
Not likely
Very likely
Not likely
1
2
3
4
5
6
7
8
9
10
Very likely
Thanks again for rating us!
Genovis Q4 2022: A First Sublicensing of Xork
Research Update
2023-02-16
08:05
Redeye returns with an updated take on the pick-and-shovel play Genovis following its partner Selecta Biosciences’ licensing deal with Astellas Pharma and the company’s Q4 2022 report. With reinforced confidence in the deal with Selecta, we have raised our base case.
FE
Filip Einarsson
Disclosures and disclaimers